Tags

Type your tag names separated by a space and hit enter

Vaginal symptoms and sexual function after tension-free vaginal tape-obturator placement: minimum 12-month follow-up.
Urology. 2013 Jan; 81(1):50-4.U

Abstract

OBJECTIVE

To examine the effect of the tension-free vaginal tape-obturator (TVT-O) on sexual function and vaginal symptoms. The effect of anti-incontinence surgery on vaginal symptoms and sexual function is controversial; these assessments are increasingly important given the Food and Drug Administration warning regarding the use of transvaginal surgical mesh.

MATERIALS AND METHODS

A retrospective review of 42 patients undergoing TVT-O with a minimum 1-year follow-up data was performed. The outcomes were assessed at baseline and 1 year postoperatively using validated questionnaires, including the International Consultation on Incontinence Questionnaire-Vaginal Symptoms, a validated measure assessing the impact of vaginal symptoms and sexual matters on quality of life and treatment outcomes. The International Consultation on Incontinence Questionnaire-Female Lower Urinary Tract Symptoms and Incontinence Impact Questionnaire, Short Form were used to assess the incontinence and quality of life outcomes, respectively.

RESULTS

Statistically significant improvements were seen in the vaginal symptoms (from 9.7 to 6.0, P=.01), sexual matters (from 16.7 to 6.9, P=.01), and quality of life (from 3.0 to 1.1, P=.001) domains on the International Consultation on Incontinence Questionnaire-Vaginal Symptoms from the baseline to 1-year assessment. Of 20 sexually active patients at baseline, 18 reported continued sexual activity postoperatively, with 2 patients reporting an absence of sexual activity because of other factors. Six patients who were not sexually active at baseline because of vaginal symptoms had resumed sexual activity at 1 year. Statistically significant improvement in vaginal soreness and a trend toward improvement in the abdominal pain domain score were seen.

CONCLUSION

TVT-O sling placement was associated with symptom stability or improvement in validated measures of sexual function and vaginal symptoms. These data do not support the concerns regarding worsening sexual function and vaginal symptoms after TVT-O sling placement.

Authors+Show Affiliations

Virginia Commonwealth University School of Medicine, Richmond, Virginia 23223, USA. aking4@mcvh-vcu.eduNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

23200972

Citation

King, Ashley B., et al. "Vaginal Symptoms and Sexual Function After Tension-free Vaginal Tape-obturator Placement: Minimum 12-month Follow-up." Urology, vol. 81, no. 1, 2013, pp. 50-4.
King AB, Wolters JP, Klausner AP, et al. Vaginal symptoms and sexual function after tension-free vaginal tape-obturator placement: minimum 12-month follow-up. Urology. 2013;81(1):50-4.
King, A. B., Wolters, J. P., Klausner, A. P., & Rapp, D. E. (2013). Vaginal symptoms and sexual function after tension-free vaginal tape-obturator placement: minimum 12-month follow-up. Urology, 81(1), 50-4. https://doi.org/10.1016/j.urology.2012.07.105
King AB, et al. Vaginal Symptoms and Sexual Function After Tension-free Vaginal Tape-obturator Placement: Minimum 12-month Follow-up. Urology. 2013;81(1):50-4. PubMed PMID: 23200972.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Vaginal symptoms and sexual function after tension-free vaginal tape-obturator placement: minimum 12-month follow-up. AU - King,Ashley B, AU - Wolters,Jeff P, AU - Klausner,Adam P, AU - Rapp,David E, Y1 - 2012/11/30/ PY - 2012/06/13/received PY - 2012/07/17/revised PY - 2012/07/27/accepted PY - 2012/12/4/entrez PY - 2012/12/4/pubmed PY - 2013/3/23/medline SP - 50 EP - 4 JF - Urology JO - Urology VL - 81 IS - 1 N2 - OBJECTIVE: To examine the effect of the tension-free vaginal tape-obturator (TVT-O) on sexual function and vaginal symptoms. The effect of anti-incontinence surgery on vaginal symptoms and sexual function is controversial; these assessments are increasingly important given the Food and Drug Administration warning regarding the use of transvaginal surgical mesh. MATERIALS AND METHODS: A retrospective review of 42 patients undergoing TVT-O with a minimum 1-year follow-up data was performed. The outcomes were assessed at baseline and 1 year postoperatively using validated questionnaires, including the International Consultation on Incontinence Questionnaire-Vaginal Symptoms, a validated measure assessing the impact of vaginal symptoms and sexual matters on quality of life and treatment outcomes. The International Consultation on Incontinence Questionnaire-Female Lower Urinary Tract Symptoms and Incontinence Impact Questionnaire, Short Form were used to assess the incontinence and quality of life outcomes, respectively. RESULTS: Statistically significant improvements were seen in the vaginal symptoms (from 9.7 to 6.0, P=.01), sexual matters (from 16.7 to 6.9, P=.01), and quality of life (from 3.0 to 1.1, P=.001) domains on the International Consultation on Incontinence Questionnaire-Vaginal Symptoms from the baseline to 1-year assessment. Of 20 sexually active patients at baseline, 18 reported continued sexual activity postoperatively, with 2 patients reporting an absence of sexual activity because of other factors. Six patients who were not sexually active at baseline because of vaginal symptoms had resumed sexual activity at 1 year. Statistically significant improvement in vaginal soreness and a trend toward improvement in the abdominal pain domain score were seen. CONCLUSION: TVT-O sling placement was associated with symptom stability or improvement in validated measures of sexual function and vaginal symptoms. These data do not support the concerns regarding worsening sexual function and vaginal symptoms after TVT-O sling placement. SN - 1527-9995 UR - https://www.unboundmedicine.com/medline/citation/23200972/Vaginal_symptoms_and_sexual_function_after_tension_free_vaginal_tape_obturator_placement:_minimum_12_month_follow_up_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0090-4295(12)01147-8 DB - PRIME DP - Unbound Medicine ER -